(293) Advancing Idiopathic Pulmonary Fibrosis treatment with PROTAC Nanomedicine

Introduction: Idiopathic Pulmonary Fibrosis is a chronic, progressive, and ultimately fatal fibrotic lung disease with a median survival time of 3–4 years after diagnosis, becoming a global concern as its prevalence appears associated with aging. ARV-825 is a PROTAC (Proteolysis-Targeting Chimeras) that offers a novel therapeutic approach for lung fibrosis by regulating pro-fibrotic gene expression in fibroblasts, inhibiting the fibroblast-to-myofibroblast transition and reducing collagen type I production. We developed a PROTAC nanomedicine for intracellular delivery targeting lung fibrosis therapy.